Common use of Validation Review Clause in Contracts

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s final Annual Report shall be initiated no later than one year after Good Shepherd’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherdany of GSK’s Claims Review IRO Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements GlaxoSmithKline LLC Corporate Integrity Agreement of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd GSK shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdGSK’s final Annual Report shall be initiated no later than one year after Good ShepherdGSK’s final submission (as described in Section IIII.B) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd GSK of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd GSK may request a meeting with OIG to: (a) discuss the results of any Claims IRO Review submissions or findings; (b) present any additional information to clarify the results of the Claims IRO Review or to correct the inaccuracy of the Claims IRO Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd GSK agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims IRO Review issues with Good Shepherd GSK prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdExtendicare’s Claims MDS Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims MDS Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims MDS Review complied with the requirements of the CIA and/or the findings or Claims MDS Review results are inaccurate (Validation Review). Good Shepherd Extendicare shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdExtendicare’s final Annual Report shall be initiated no later than one year after Good ShepherdExtendicare’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Extendicare of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Extendicare may request a meeting with OIG to: (a) discuss the results of any Claims MDS Review submissions or findings; (b) present any additional information to clarify the results of the Claims MDS Review or to correct the inaccuracy of the Claims MDS Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Extendicare agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims MDS Review issues with Good Shepherd Extendicare prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdDignity Health’s Claims Review or Inpatient Medical Necessity and Appropriateness Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings findings, Claims Review results, or Claims Inpatient Medical Necessity and Appropriateness Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Inpatient Medical Necessity and Appropriateness Review complied with the requirements of the CIA and/or the findings or findings, Claims Review results results, or Inpatient Medical Necessity and Appropriateness Review are inaccurate (Validation Review). Good Shepherd Dignity Health shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review Corporate Integrity Agreement Dignity Health of Reports submitted as part of Good ShepherdDignity Health’s final Annual Report shall be initiated no later than one year after Good ShepherdDignity Health’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Dignity Health of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Dignity Health may request a meeting with OIG to: (a) discuss the results of any Claims Review or Inpatient Medical Necessity and Appropriateness Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Inpatient Medical Necessity and Appropriateness Review to correct the inaccuracy of the Claims Review or Inpatient Medical Necessity and Appropriateness Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Dignity Health agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.4 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Inpatient Medical Necessity and Appropriateness Review issues with Good Shepherd Dignity Health prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdRMC’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd RMC shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdRMC’s final Annual Report shall be initiated no later than one year after Good ShepherdRMC’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd RMC of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd RMC may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd RMC agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd RMC prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherda Provider’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Alliance/Active/Xxxxx/Xxxx/Xxxxxx Corporate Integrity Agreement Cost Review results are inaccurate (Validation Review). Good Shepherd The Provider shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherdthe Provider’s final Annual Report shall be initiated no later than one year after Good Shepherdthe Provider’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd the Provider of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd the Provider may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd The Provider agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd the Provider prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdEnsign Group’s Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd Ensign Group shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdEnsign Group’s final Annual Report shall be initiated no later than one year after Good ShepherdEnsign Group’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Ensign Group of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Ensign Group may request a meeting with OIG, and OIG shall meet with Ensign Group prior to its Validation Review to: (a) discuss the results of any Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review or to correct the inaccuracy of the Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Ensign Group agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review issues with Good Shepherd Ensign Group prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdExactech’s Claims Arrangements Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Arrangements Review results are inaccurate (Validation Review). Good Shepherd Exactech shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdExactech’s final Annual Report shall be initiated no later than one year after Good ShepherdExactech’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Exactech of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Exactech may request a meeting with OIG to: (a) discuss the results of any Claims Arrangements Review submissions or findings; (b) present any additional information to clarify the results of the Claims Arrangements Review or to correct the inaccuracy of the Claims Arrangements Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Exactech agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3. in an expedited manner. OIG will attempt in good faith to resolve any Claims Arrangements Review issues with Good Shepherd Exactech prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdRehab’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Rehab shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdRehab’s final Annual Report shall be initiated no later than one year after Good ShepherdRehab’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Rehab of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Rehab may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Rehab agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Rehab prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdGambro’s Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review fails to conform to the requirements of this CIAAgreement; or (b) Gambro’s or the IRO’s findings or Heightened Arrangements Reviewed results, Claims Review results, Unallowable Cost Review results, or Stat Lab Systems Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review complied with the requirements of the CIA Agreement and/or the findings or Heightened Arrangements Review results, Claims Review results, Unallowable Cost Review results, or Stat Lab Systems Review results are inaccurate (Validation Review). Good Shepherd Gambro shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdGambro’s final Annual Report shall be initiated no later than one year after Good ShepherdGambro’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Gambro of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Gambro may request a meeting with OIG to: (a) discuss the results of any Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review submissions or findings; (b) present any additional information to clarify the results of the Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review or to correct the inaccuracy of the Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Gambro agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Heightened Arrangements Review, Claims Review, Unallowable Cost Review, or Stat Lab Systems Review issues with Good Shepherd Gambro prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd AstraZeneca shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdAstraZeneca’s Corporate Integrity Agreement AstraZeneca final Annual Report shall be initiated no later than one year after Good ShepherdAstraZeneca’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd AstraZeneca of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd AstraZeneca may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims applicable Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd AstraZeneca agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd AstraZeneca prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdOrbit’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Orbit shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdOrbit’s final Annual Report shall be initiated no later than one year after Good ShepherdOrbit’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Orbit of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Orbit may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Orbit agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Orbit prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdCHSI’s Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd CHSI shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCHSI’s final Annual Report shall be initiated no later than one year after Good ShepherdCHSI’s final submission (as described in Section II) is received by OIG. Community Health Systems, Inc. Corporate Integrity Agreement Prior to initiating a Validation Review, OIG shall notify Good Shepherd CHSI of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CHSI may request a meeting with OIG to: (a) discuss the results of any Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review or to correct the inaccuracy of the Claims Inpatient Medical Necessity and Appropriateness Review , Arrangements Review, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CHSI agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.6in an expedited manner. OIG will attempt in good faith to resolve any Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review issues with Good Shepherd CHSI prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdeTEL-Rx’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd eTEL-Rx shall pay for the reasonable cost of eTEL-Rx Corporate Integrity Agreement any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdeTEL-Rx’s final Annual Report shall be initiated no later than one year after Good ShepherdeTEL-Rx’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd eTEL-Rx of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd eTEL-Rx may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd xXXX-Xx agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd eTEL-Rx prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdSpecialized’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (“Validation Review”). Good Shepherd shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s final Annual Report shall be initiated no later than one year after Good Shepherd’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Amedisys of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Amedisys may request a meeting with OIG to: (a) to discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional or relevant information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review; and/or (c) or propose alternatives to the proposed Validation Review. Good Shepherd agrees to Amedisys shall provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues or Unallowable Cost Review with Good Shepherd Amedisys prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. Amedisys shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents so Amedisys, Inc. and Amedisys Specialized Medical Services, Inc. Corporate Integrity Agreement 11 long as it is initiated within one year after Amedisys’ final submission (as described in Section II) is received by OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdOrbit’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Orbit shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdOrbit’s final Annual Report shall be initiated no later than one year after Good ShepherdXxxxx’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Orbit of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Xxxxx may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Xxxxx agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Orbit prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherdany of Baxano Surgical’s Claims Review IRO Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Baxano Surgical shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdBaxano Surgical’s final Annual Report shall be initiated no later than one year after Good ShepherdBaxano Surgical’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Baxano Surgical of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Baxano Surgical may request a meeting with OIG to: (a) discuss the results of any Claims IRO Review submissions or findings; (b) present any additional information to clarify the results of the Claims IRO Review or to correct the inaccuracy of the Claims IRO Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Baxano Surgical agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims IRO Review issues with Good Shepherd Baxano Surgical prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any Focus Arrangements Review fails to conform to the requirements of this CIA; or (b) the Legal IRO’s findings or Claims Focus Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Focus Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Focus Arrangements Review results are inaccurate (Validation Review). Good Shepherd Envision shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports a Focus Arrangements Review submitted as part of Good ShepherdEnvision’s final Annual Report shall be initiated no later than one year after Good ShepherdEnvision’s final submission (as described in Section II) is received by OIG. Envision Corporate Integrity Agreement 13 Prior to initiating a Validation Review, OIG shall notify Good Shepherd Envision in writing of its intent to do so and provide a written an explanation of why the reasons OIG believes such has determined a review Validation Review is necessary. To resolve any concerns raised by Envision shall have 30 days following the date of the OIG, Good Shepherd may request ’s written notice to submit a meeting with written response to OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present that includes any additional or relevant information to clarify the results of the Claims Focus Arrangements Review or to correct the inaccuracy of the Claims Review; Focus Arrangements Review and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the The final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdCHSI’s Claims Review, Arrangements Review, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review, Arrangements Review, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review, Arrangements Review, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review, Arrangements Review, or Unallowable Community Health Systems, Inc. Corporate Integrity Agreement, Amended Cost Review results are inaccurate (Validation Review). Good Shepherd CHSI shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCHSI’s final Annual Report shall be initiated no later than one year after Good ShepherdCHSI’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CHSI of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CHSI may request a meeting with OIG to: (a) discuss the results of any Claims Review, Arrangements Review, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review, Arrangements Review, or Unallowable Cost Review or to correct the inaccuracy of the Claims Review, Arrangements Review, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CHSI agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.6in an expedited manner. OIG will attempt in good faith to resolve any Claims Review, Arrangements Review, or Unallowable Cost Review issues with Good Shepherd CHSI prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdIHS’s Claims Arrangements Review fails to conform to the requirements of this CIA; or (b) the Legal IRO’s findings or Claims Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Arrangements Review results are inaccurate (Validation Review). Good Shepherd IHS shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdIHS’s final Annual Report shall be initiated no later than one year after Good ShepherdIHS’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd IHS of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd IHS may request a meeting with OIG to: (a) discuss the results of any Claims Arrangements Review submissions or findings; (b) present any additional information to clarify the results of the Claims Arrangements Review or to correct the inaccuracy of the Claims Arrangements Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd IHS agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Arrangements Review issues with Good Shepherd IHS prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherdany of InterMune’s Claims Review IRO Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review in question complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd InterMune shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdInterMune’s final Annual Report shall must be initiated no later than one year after Good ShepherdInterMune’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd InterMune of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd InterMune may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review in question or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd InterMune agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims IRO Review issues with Good Shepherd InterMune prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdXxxxxxx Lutheran’s Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Xxxxxxx Lutheran Corporate Integrity Agreement MDS Review, Therapy Systems Assessment, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd Xxxxxxx Lutheran shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdXxxxxxx Lutheran’s final Annual Report shall be initiated no later than one year after Good ShepherdXxxxxxx Lutheran’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Xxxxxxx Lutheran of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Xxxxxxx Lutheran may request a meeting with OIG to: (a) discuss the results of any Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review or to correct the inaccuracy of the Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Xxxxxxx Lutheran agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.6 in an expedited manner. OIG will attempt in good faith to resolve any Claims MDS Review, Therapy Systems Assessment, or Unallowable Cost Review issues with Good Shepherd Xxxxxxx Lutheran prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherdthe IRO’s Claims Review, or the IRO’s Restocking Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or findings, Claims Review and/or Restocking Review results are inaccurate, ; OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review and/or Restocking Review complied with the requirements of the CIA and/or the findings or of the Claims Review and/or Restocking Review results are inaccurate (Validation Review). Good Shepherd CareMed shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCareMed’s final Annual Report shall be initiated no later than one year after Good ShepherdCareMed’s final submission (as described above in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CareMed of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CareMed may request a meeting with OIG to: (a) discuss the results of any Claims Review and/or Restocking Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review and/or Restocking Review or to correct the inaccuracy of the Claims Review and/or Restocking Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CareMed agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review and/or Restocking Review issues with Good Shepherd CareMed prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s any Arrangements Review or Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Arrangements Review results or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Arrangements Review or Claims Review complied with the requirements of the CIA and/or the findings or Arrangements Review or Claims Review results are inaccurate (Validation Review). Good Shepherd Home Bound shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports an Arrangements Review or Claims Review submitted as part of Good ShepherdHome Bound’s final Annual Report shall be initiated no later than one year after Good ShepherdHome Bound’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Home Bound in writing of its intent to do so and provide a written an explanation of why the reasons OIG believes such has determined a review Validation Review is necessary. To resolve any concerns raised by Home Bound shall have 30 days following the date of the OIG, Good Shepherd may request ’s written notice to submit a meeting with written response to OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present that includes any additional or relevant information to clarify the results of the Arrangements Review or Claims Review or to correct the inaccuracy of the Arrangements Review or Claims Review; Review and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the The final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdLHC’s Internal Compliance Audit Review, Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Internal Compliance Audit Review or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Internal Compliance Audit Review, Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd LHC shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdLHC’s final Annual Report shall be initiated no later than one year after Good ShepherdLHC’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd LHC of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd LHC may request a meeting with OIG to: (a) discuss the results of any Internal Compliance Audit, Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Internal Compliance Audit, Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Internal Compliance Audit, Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd LHC agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Internal Compliance Audit, Claims Review or Unallowable Cost Review issues with Good Shepherd LHC prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd AtriCure, Inc. shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdAtriCure, Inc.’s final Annual Report shall be initiated no later than one year after Good ShepherdAtriCure, Inc.’s final submission (as described in Section II) is received by OIG. CORPORATE INTEGRITY AGREEMENT ATRICURE, INC. Prior to initiating a Validation Review, OIG shall notify Good Shepherd AtriCure, Inc. of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd AtriCure, Inc. may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims applicable Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd AtriCure, Inc. agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd AtriCure, Inc. prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Spectranetics shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s Spectranetics’ final Annual Report shall be initiated no later than one year after Good Shepherd’s Spectranetics’ final submission (as described in Section II) is received by OIG. Spectranetics Corporate Integrity Agreement Prior to initiating a Validation Review, OIG shall notify Good Shepherd Spectranetics of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Spectranetics may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims applicable Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Spectranetics agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Spectranetics prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Harmony-Xxxxxx’x Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd Harmony-Xxxxxx shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s Harmony-Xxxxxx’x final Annual Report shall be initiated no later than one year after Good Shepherd’s Harmony-Xxxxxx’x final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Harmony-Xxxxxx of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Harmony-Xxxxxx may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees Harmony-Xxxxxx agree to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd Harmony-Xxxxxx prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdCHN’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd CHN shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCHN’s final Annual Report shall be initiated no later than one year after Good ShepherdCHN’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CHN of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CHN may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CHN agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd CHN prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Zxxxxx’x Arrangements Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Arrangements Review Corporate Integrity Agreement between OIG-HHS and Zxxxxx, Inc. results are inaccurate (Validation Review). Good Shepherd Zimmer shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s Zxxxxx’x final Annual Report shall must be initiated no later than one year after Good Shepherd’s Zxxxxx’x final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Zimmer of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Zimmer may request a meeting with OIG to: (a) discuss the results of any Claims Arrangements Review submissions or findings; (b) present any additional information to clarify the results of the Claims Arrangements Review or to correct the inaccuracy of the Claims Arrangements Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Zimmer agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Arrangements Review issues with Good Shepherd Zimmer prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdCHSI’s Claims Review, Arrangements Review, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review, Arrangements Review, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review, Arrangements Review, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review, Arrangements Review, or Unallowable‌ Cost Review results are inaccurate (Validation Review). Good Shepherd CHSI shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCHSI’s final Annual Report shall be initiated no later than one year after Good ShepherdCHSI’s final submission (as described in Section Section‌‌ II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CHSI of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CHSI may request a meeting with OIG to: (a) discuss the results of any Claims Review, Arrangements Review, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review, Arrangements Review, or Unallowable Cost Review or to correct the inaccuracy of the Claims Review, Arrangements Review, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CHSI agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.6in an expedited manner. OIG will attempt in good faith to resolve any Claims Review, Arrangements Review, or Unallowable Cost Review issues with Good Shepherd CHSI prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s the CareAll Entities’ Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd The CareAll Entities shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s the CareAll Entities’ final Annual Report shall be initiated no later than one year after Good Shepherd’s the CareAll Entities’ final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd the CareAll Entities of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd the CareAll Entities may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees The CareAll Entities agree to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd the CareAll Entities prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s the IRO's Cardiac Test Procedures Review or Claims Review fails to conform to the requirements of this CIAIA; or (b) the IRO’s findings 's Cardiac Test Procedures Review or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Cardiac Test Procedures Review or the Claims Review complied with the requirements of the CIA IA and/or the findings of the Cardiac Test Procedures Review or the Claims Review results are inaccurate (Validation Review). Good Shepherd The Providers shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s the Providers’ final Annual Report shall be initiated no later than one year after Good Shepherd’s the Providers’ final submission (as described above in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd the Providers of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd the Providers may request a meeting with OIG to: (a) discuss the results of any Cardiac Test Procedures Review or Claims Review Review, submissions or findings; (b) present any additional information to clarify the results of the Cardiac Test Procedures Review or Claims Review Review, or to correct the inaccuracy of the Cardiac Procedures Review or Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees The Providers agree to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any Cardiac Test Procedures Review or Claims Review issues with Good Shepherd the Providers prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Lilly shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdLilly’s final Annual Report shall be initiated no later than one year after Good ShepherdLilly’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Lilly of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Lilly may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims applicable Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Lilly agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Lilly prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. 4.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdPharMerica’s Claims Review Covered Transactions Procedure fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Covered Transactions Review results Report are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Covered Transactions Review complied with the requirements of the CIA and/or the findings or Claims Covered Transactions Review results Report are inaccurate (“Validation Review”). Good Shepherd PharMerica shall pay for the reasonable cost of any such review Validation Review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s final Annual Report shall must be initiated no later than one year after Good ShepherdPharMerica’s final submission (as described in Section IIII of this CIA) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd PharMerica of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd PharMerica may request a meeting with OIG to: (a) discuss the results of any Claims Covered Transactions Review submissions or findingsCovered Transactions Review Report; (b) present any additional information to clarify the results of the Claims Covered Transactions Review or to correct the inaccuracy of the Claims ReviewCovered Transactions Review Report; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd PharMerica agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Covered Transactions Review issues with Good Shepherd PharMerica prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Biomet Orthopedics’ Arrangements Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Arrangements Review results are inaccurate (Validation Review). Good Shepherd Biomet Orthopedics shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s Biomet Orthopedics’ final Annual Report shall must be initiated no later than one year after Good Shepherd’s Biomet Orthopedics’ final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Biomet of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Biomet Orthopedics may request a meeting with OIG to: (a) discuss the results of any Claims Arrangements Review submissions or findings; (b) present any additional information to clarify the results of the Claims Arrangements Review or to correct the inaccuracy of the Claims Arrangements Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Biomet Orthopedics agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Arrangements Review issues with Good Shepherd Biomet Orthopedics prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdRotech’s Claims Review and/or Unallowable Cost Review, if applicable, fails to conform Rotech Healthcare Inc. Corporate Integrity Agreement to the requirements of this CIA; or (b) the IRO’s findings or results of its Claims Review results and/or Unallowable Cost Review are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review and/or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or results of the Claims Review results and/or Unallowable Cost Review are inaccurate (Validation Review). Good Shepherd Rotech shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdRotech’s final Annual Report shall be initiated no later than one year after Good ShepherdRotech’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Rotech of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Rotech may request a meeting with OIG to: (a) discuss the results of any Claims Review and/or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review and/or Unallowable Cost Review or to correct the inaccuracy of the Claims Review and/or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Rotech agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.6 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review and/or Unallowable Cost Review issues with Good Shepherd Rotech prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event the OIG has reason to believe that: (a) Good Shepherd’s Claims Review Rotech's ACA fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results ACA Final Report(s) are inaccurate, the OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied ACA complies with the requirements of the CIA and/or the findings or Claims Review results ACA Final Report(s) are inaccurate (Validation Review)inaccurate. Good Shepherd shall Rotech agrees to pay for the reasonable cost of any such review performed by the OIG or any of its designated agents. Any Validation Review of Reports submitted agents so long as part of Good Shepherd’s final Annual Report shall be it is initiated no later than before one year after Good Shepherd’s Rotech's final submission (as described in Section section II) is received by the OIG. Prior to initiating a Validation Review, the OIG shall notify Good Shepherd Rotech of its intent to do so and provide a written an explanation of for believing why OIG believes such a review is necessary. To In order to resolve any concerns raised by the OIG, Good Shepherd Rotech may request a meeting with the OIG to: (a) to discuss the results of any Claims Review ACA submissions or findingsany ACA Final Report(s); (b) present any additional or relevant information to clarify the results of the Claims Review ACA or to correct the inaccuracy of the Claims ReviewACA Final Report(s); and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Rotech agrees to provide any additional information as may be requested by the OIG under this Section III.D.3 section in an expedited manner. The OIG will attempt in good faith to resolve any Claims Review issues related to the ACA with Good Shepherd Rotech prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of the OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdCHSI’s Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Community Health Systems, Inc. Corporate Integrity Agreement Cost Review results are inaccurate (Validation Review). Good Shepherd CHSI shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCHSI’s final Annual Report shall be initiated no later than one year after Good ShepherdCHSI’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CHSI of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CHSI may request a meeting with OIG to: (a) discuss the results of any Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review or to correct the inaccuracy of the Claims Inpatient Medical Necessity and Appropriateness Review , Arrangements Review, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CHSI agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.6in an expedited manner. OIG will attempt in good faith to resolve any Claims Inpatient Medical Necessity and Appropriateness Review, Arrangements Review, or Unallowable Cost Review issues with Good Shepherd CHSI prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims an IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims IRO Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims IRO Review complied with the requirements of the CIA and/or the findings or Claims the IRO Review results are inaccurate (Validation Review). Good Shepherd EGS shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdEGS’s final Annual Report shall be initiated no later than one year after Good ShepherdEGS’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd EGS of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd EGS may request a meeting with OIG to: (a) discuss the results of any Claims IRO Review submissions or findings; (b) present any additional information to clarify the results of the Claims IRO Review or to correct the inaccuracy of the Claims IRO Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd EGS agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.G.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims IRO Review issues with Good Shepherd EGS prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdCVS Caremark’s Third-Party Liability Claims Review or PBM Platform Controls Assessment fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Third-Party Liability Claims Review or PBM Platform Controls Assessment results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Third-Party Liability Claims Review or PBM Platform Controls Assessment complied with the requirements of the CIA and/or the IRO’s findings or Third-Party Liability Claims Review or PBM Platform Controls Assessment results are inaccurate (Validation Review). Good Shepherd CVS Caremark shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdCVS Caremark’s final Annual Report shall be initiated no later than one year after Good ShepherdCVS Caremark’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CVS Caremark of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CVS Caremark may request a meeting with OIG to: (a) discuss the results of any Third-Party Liability Claims Review or PBM Platform Controls Assessment submissions or findings; (b) present any additional information to clarify the results of the Third-Party Liability Claims Review or PBM Platform Controls Assessment or to correct the inaccuracy of the Third-Party Liability Claims ReviewReview or PBM Platform Controls Assessment; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CVS Caremark agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.4 in an expedited manner. OIG will attempt in good faith to resolve any Third-Party Liability Claims Review or PBM Platform Controls Assessment issues with Good Shepherd CVS Caremark prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event the OIG has reason to believe that: (a) Good Shepherd’s Claims the Verification Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) Odyssey and/or the IROIVO’s findings or Claims Review results are inaccurate, the OIG may, at its sole discretion, conduct its own review to determine whether the Claims Verification Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review review results are inaccurate (“Validation Review”). Good Shepherd shall Odyssey agrees to pay for the reasonable cost of any such review performed by the OIG or any of its designated agents. Any Validation Review of Reports submitted agents so long as part of Good Shepherd’s final Annual Report shall be it is initiated no later than before one year after Good ShepherdOdyssey’s final submission (as described in Section II) is received by the OIG. Prior to initiating a Validation Review, the OIG shall notify Good Shepherd Odyssey of its intent to do so and provide a written explanation of why the OIG believes such a review is necessary. To resolve any concerns raised by the OIG, Good Shepherd Odyssey may request a meeting with the OIG to: (a) to discuss the results of any Claims Verification Review or Unallowable Cost Review submissions or findings; (b) present any additional or relevant information to clarify Odyssey Corporate Integrity Agreement the results of the Claims Verification Review or Unallowable Cost Review or to correct the inaccuracy inaccuracies of the Claims Verification Review or the Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Odyssey agrees to provide any additional information as may be requested by the OIG under this Section III.D.3 section in an expedited manner. The OIG will attempt in good faith to resolve any Claims Verification Review issues or Unallowable Cost Review with Good Shepherd Odyssey prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of the OIG.

Validation Review. In the event OIG has reason to believe reasonably believes that: (a) Good ShepherdFamily Dermatology’s Claims Arrangements Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Arrangements Review results are inaccurate (Validation Review). Good Shepherd Family Dermatology shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdFamily Dermatology’s final Annual Report shall be initiated no later than one year after Good ShepherdFamily Dermatology’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Family Dermatology of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Family Dermatology may request a meeting with OIG to: (a) discuss the results of any Claims Arrangements Review submissions or findings; (b) present any additional information to clarify the results of the Claims Arrangements Review or to correct the inaccuracy of the Claims Arrangements Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Family Dermatology agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.F.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Arrangements Review issues with Good Shepherd Family Dermatology prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event the OIG has reason to believe that: (a) Good Shepherd’s Mariner's Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s 's or Mariner's internal audit findings or Claims Review results are inaccurate, the OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate ("Validation Review"). Good Shepherd shall Mariner agrees to pay for the reasonable cost of any such review performed by the OIG or any of its designated agents. Any Validation Review of Reports submitted agents so long as part of Good Shepherd’s final Annual Report shall be it is initiated no later than before one year after Good Shepherd’s Mariner's final submission (as described in Section section II) is received by the OIG. Prior to initiating a Validation Review, the OIG shall notify Good Shepherd Mariner of its intent to do so and provide a written explanation of why the OIG believes such a review is necessary. To resolve any concerns raised by the OIG, Good Shepherd Mariner may request a meeting with the OIG to: (a) to discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional or relevant information to clarify the results of the Claims Review or Unallowable Cost Review to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Mariner agrees to provide any additional information as may be requested by the OIG under this Section III.D.3 section in an expedited manner. The OIG will attempt in good faith to resolve any Claims Review issues or Unallowable Cost Review with Good Shepherd Mariner prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of the OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Xxx Xxxxxx’x Claims Review or Surgical Procedures Quality Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or the Claims Review or Surgical Procedures Quality Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Surgical Procedures Quality Review complied with the requirements of the CIA and/or the IRO’s findings or Claims Review or Surgical Procedures Quality Review results are inaccurate (Validation Review). Good Shepherd Mid Xxxxxx shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s Mid Xxxxxx’x final Annual Report shall be initiated no later than one year after Good Shepherd’s Xxx Xxxxxx’x final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Mid Xxxxxx of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Xxx Xxxxxx may request a meeting with OIG to: (a) discuss the results of any Claims Review or Surgical Procedures Quality Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Surgical Procedures Quality Review, or to correct the inaccuracy of the Claims Review or Surgical Procedures Quality Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Xxx Xxxxxx agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.4 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Surgical Procedures Quality Review issues with Good Shepherd Mid Xxxxxx prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event HHS-OIG has reason to believe that: (a) Good ShepherdMedco’s Claims Focus Arrangements Review or Unallowable Cost Review fails to conform to the requirements of this CIAAgreement; or (b) the IRO’s findings or Claims the Focus Arrangements Review or Unallowable Cost Review results are inaccurate, HHS-OIG may, at its sole discretion, conduct its own review to determine whether the Claims Focus Arrangements Review or Unallowable Cost Review complied with the requirements of the CIA Agreement and/or the findings or Claims Focus Arrangements Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd Medco shall pay for the reasonable cost of any such review performed by HHS-OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdMedco’s final Annual Report shall must be initiated no later than one year after Good ShepherdMedco’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, HHS-OIG shall notify Good Shepherd Medco of its intent to do so and provide a written explanation of why HHS-OIG believes such a review is necessary. To resolve any concerns raised by HHS-OIG, Good Shepherd Medco may request a meeting with HHS-OIG to: (a) discuss the results of any Claims Focus Arrangements Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Focus Arrangements Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Focus Arrangements Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Medco agrees to provide any additional information as may be requested by HHS-OIG under this Section III.D.3 in an expedited manner. HHS-OIG will attempt in good faith to resolve any Claims Focus Arrangements Review or Unallowable Cost Review issues with Good Shepherd Medco prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of HHS-OIG.. Medco CIA

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdMedicus’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Medicus shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdMedicus’s final Annual Report shall be initiated no later than one year after Good ShepherdMedicus’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Medicus of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Medicus may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Medicus agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Medicus prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherdthe IRO’s Claims Review, or the IRO’s Restocking Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or findings, Claims Review and/or Restocking Review results are inaccurate, ; OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review and/or Restocking Review complied with the requirements of the CIA and/or the findings or of the Claims Review and/or Restocking Review results are inaccurate (Validation Review). Good Shepherd CareMed shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Corporate Integrity Agreement between the Office of Inspector General and Sorkin’s Rx Ltd. d/b/a CareMed Pharmaceutical Services Validation Review of Reports submitted as part of Good ShepherdCareMed’s final Annual Report shall be initiated no later than one year after Good ShepherdCareMed’s final submission (as described above in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd CareMed of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd CareMed may request a meeting with OIG to: (a) discuss the results of any Claims Review and/or Restocking Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review and/or Restocking Review or to correct the inaccuracy of the Claims Review and/or Restocking Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd CareMed agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review and/or Restocking Review issues with Good Shepherd CareMed prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdWalgreens’s Claims Government Reimbursement Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Government Reimbursement Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Government Reimbursement Review complied with the requirements of the this CIA and/or the findings or Claims Government Reimbursement Review results are inaccurate (Validation Review). Good Shepherd Walgreens shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdWalgreens’s final Annual Report shall must be initiated no later than one year after Good ShepherdWalgreens’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Walgreens of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Walgreens may request a meeting with OIG to: (a) discuss the results of any Claims Government Reimbursement Review submissions or findings; (b) present any additional information to clarify the results of the Claims Government Reimbursement Review or to correct the inaccuracy of the Claims Government Reimbursement Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Walgreens agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Government Reimbursement Review issues with Good Shepherd Walgreens prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdXxxxxxxxxx Regional’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd Xxxxxxxxxx Regional shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdXxxxxxxxxx Regional’s final Annual Report shall be initiated no later than one year after Good ShepherdXxxxxxxxxx Regional’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Xxxxxxxxxx Regional of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Xxxxxxxxxx Regional may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Xxxxxxxxxx Regional agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd Xxxxxxxxxx Regional prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event the OIG has reason to believe that: (a) Good ShepherdAllina’s Annual Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, the OIG may, at its sole discretion, conduct its own review to determine whether the Annual Claims Review complied complies with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review)inaccurate. Good Shepherd shall Allina agrees to pay for the reasonable cost of any such review performed by the OIG or any of its designated agents. Any Validation Review of Reports submitted agents so long as part of Good Shepherd’s final Annual Report shall be it is initiated no later than before one year after Good Shepherd’s the final submission (as described in Section II) is received by the OIG. Prior to initiating a Validation ReviewReview under this Section III.D.4.b, the OIG shall notify Good Shepherd Allina of its intent to do so and provide a written explanation of why the OIG believes such a review is necessary. To resolve any concerns raised by the OIG, Good Shepherd Allina may request a meeting with the OIG to: (a) to discuss the results of any Claims Review submissions or findings; (b) present any additional or relevant information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Allina agrees to provide any additional information as may be requested by the OIG under this Section III.D.3 in an expedited manner. The OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Allina prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of the OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdHill-Rom’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Hill-Rom shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdHill-Rom’s final Annual Report shall be initiated no later than one year after Good ShepherdHill-Rom’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Hill-Rom of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Hill-Rom may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims ReviewClaims; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Hill-Rom agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Hill-Rom prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherdany of Amgen’s Claims Review IRO Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Amgen shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdXxxxx’s final Annual Report shall be initiated no later than one year after Good ShepherdXxxxx’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Amgen of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Amgen may request a meeting with OIG to: (a) discuss the results of any Claims IRO Review submissions or findings; (b) present any additional information to clarify the results of the Claims IRO Review or to correct the inaccuracy of the Claims IRO Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Amgen agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims IRO Review issues with Good Shepherd Amgen prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any Focus Arrangements Review fails to conform to the requirements of this CIA; or (b) the Legal IRO’s findings or Claims Focus Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Focus Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Focus Arrangements Review results are inaccurate (Validation Review). Good Shepherd Envision shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports a Focus Arrangements Review submitted as part of Good ShepherdEnvision’s final Annual Report shall be initiated no later than one year after Good ShepherdEnvision’s final submission (as described in Section II) is received by OIG. Envision Corporate Integrity Agreement 13 Prior to initiating a Validation Review, OIG shall notify Good Shepherd Envision in writing of its intent to do so and provide a written an explanation of why the reasons OIG believes such has determined a review Validation Review is necessary. To resolve any concerns raised by Envision shall have 30 days following the date of the OIG, Good Shepherd may request ’s written notice to submit a meeting with written response to OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present that includes any additional or relevant information to clarify the results of the Claims Focus Arrangements Review or to correct the inaccuracy of the Claims Review; Focus Arrangements Review and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the The final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG. 4.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims applicable IRO Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd Lilly shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdLilly’s final Annual Report shall be initiated no later than one year after Good ShepherdLilly’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Lilly of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Lilly may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims applicable Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Lilly agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd Lilly prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Xxxxxxx-Xxxxxx’x Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd Xxxxxxx-Xxxxxx shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s Xxxxxxx-Xxxxxx’x final Annual Report shall be initiated no later than one year after Good Shepherd’s Xxxxxxx-Xxxxxx’x final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Harmony-Xxxxxx of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Xxxxxxx-Xxxxxx may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees Xxxxxxx-Xxxxxx agree to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd Xxxxxxx-Xxxxxx prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdMaxim’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, or (c) Maxim’s Verification Review findings are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or CIA, the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, and/or Maxim’s Verification Review findings or results are inaccurate (Validation Review). Good Shepherd Maxim shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdMaxim’s final Annual Report shall be initiated no later than one year after Good ShepherdMaxim’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Maxim of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Maxim may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings, or of any Verification Review findings; (b) present any additional information to clarify the results of the Claims Review, Unallowable Cost Review, or Verification Review or to correct the inaccuracy of the Claims Review, Unallowable Cost Review, or Verification Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Maxim agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.6 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review, Unallowable Cost Review, or Verification Review issues with Good Shepherd Maxim prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Review any of the required Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review the results of the Reviews are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review at issue complied with the requirements of the CIA and/or the findings or Claims the results of the Review results are inaccurate (Validation Review). Good Shepherd WellCare shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdWellCare’s final Annual Report shall be initiated no later than one year after Good ShepherdWellCare’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd WellCare of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd WellCare may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims any Review or to correct the inaccuracy of the Claims any Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd WellCare agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.6 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd WellCare prior to conducting a Validation Review. However, the Corporate Integrity Agreement WellCare Health Plans, Inc. final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s the DIG Entities’ Arrangements Review, Claims Review, or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Arrangements Review, Claims Review, or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Arrangements Review, Claims Review, or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Arrangements Review, Claims Review, or Unallowable Cost Review results are inaccurate (Validation Review). Good Shepherd The DIG Entities shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s the DIG Entities’ final Annual Report shall be initiated no later than one year after Good Shepherd’s the DIG Entities’ final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd the DIG Entities of its their intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd the DIG Entities may request a meeting with OIG to: (a) discuss the results of any Arrangements Review, Claims Review, or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Arrangements Review, Claims Review, or Unallowable Cost Review or to correct the inaccuracy of the Arrangements Review, Claims Review, or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees The DIG Entities agree to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.6 in an expedited manner. OIG will attempt in good faith to resolve any Arrangements Review, Claims Review, or Unallowable Cost Review issues with Good Shepherd the DIG Entities prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdUSPh’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the IRO’s findings or Claims Review results are inaccurate (Validation Review). Good Shepherd USPh shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdUSPh’s final Annual Report shall be initiated no later than one year after Good ShepherdUSPh’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd USPh of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd USPh may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd USPh agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd USPh prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any Focus Arrangements Review fails to conform to the requirements of this CIA; or (b) the Legal IRO’s findings or Claims Focus Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Focus Arrangements Review complied with the requirements of the CIA and/or the findings or Claims Focus Arrangements Review results are inaccurate (Validation Review). Good Shepherd Envision shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports a Focus Arrangements Review submitted as part of Good ShepherdEnvision’s final Annual Report shall be initiated no later than one year after Good ShepherdEnvision’s final submission (as described in Section II) is received by OIG. OIG.‌ Prior to initiating a Validation Review, OIG shall notify Good Shepherd Envision in writing of its intent to do so and provide a written an explanation of why the reasons OIG believes such has determined a review Validation Review is necessary. To resolve any concerns raised by Envision shall have 30 days following the date of the OIG, Good Shepherd may request ’s written notice to submit a meeting with written response to OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present that includes any additional or relevant information to clarify the results of the Claims Focus Arrangements Review or to correct the inaccuracy of the Claims Review; Focus Arrangements Review and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the The final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdAmerigroup’s Claims Marketing Review or Enrollment Initiative Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Marketing Review or Enrollment Initiative Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Marketing Review or Enrollment Initiative Review complied with the requirements of the CIA and/or the findings or Claims Marketing Review or Enrollment Initiative Review results are inaccurate (Validation Review). Good Shepherd Amerigroup shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdAmerigroup’s final Annual Report shall be initiated no later than one year after Good ShepherdAmerigroup’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Amerigroup of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Amerigroup may request a meeting with OIG to: (a) discuss the results of any Claims Marketing Review or Enrollment Initiative Review submissions or findings; (b) present any additional information to clarify the results of the Claims Marketing Review or Enrollment Initiative Review or to correct the inaccuracy of the Claims Marketing Review or Enrollment Initiative Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Amerigroup agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.D.6 in an expedited manner. OIG will attempt in good faith to resolve any Claims Marketing Review or Enrollment Initiative Review issues with Good Shepherd Amerigroup prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims any IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s Endo Pharmaceuticals Inc. Corporate Integrity Agreement findings or Claims IRO Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims IRO Review complied with the requirements of the CIA and/or the IRO’s findings or Claims IRO Review results are inaccurate (Validation Review). Good Shepherd Endo shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdEPI’s final Annual Report shall be initiated no later than one year after Good ShepherdEPI’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Endo of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Xxxx may request a meeting with OIG to: (a) discuss the results of any Claims the IRO Review submissions or findings; (b) present any additional information to clarify the results of the Claims IRO Review or to correct the inaccuracy of the Claims IRO Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Xxxx agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims IRO Review issues with Good Shepherd Endo prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

Validation Review. In the event OIG has reason to believe that: (a) Good ShepherdAmedisys’s Claims Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Claims Review or Unallowable Amedisys, Inc. and Amedisys Holding, LLC Corporate Integrity Agreement Cost Review results are inaccurate (Validation Review). Good Shepherd Amedisys shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good ShepherdAmedisys’s final Annual Report shall be initiated no later than one year after Good ShepherdAmedisys’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd Amedisys of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd Amedisys may request a meeting with OIG to: (a) discuss the results of any Claims Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or Unallowable Cost Review or to correct the inaccuracy of the Claims Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd Amedisys agrees to provide any additional information as may be requested by OIG under this Section III.D.3 III.E.5 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review or Unallowable Cost Review issues with Good Shepherd Amedisys prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.